1. Almog, Y. et al. Plasma level of N terminal pro-brain natriuretic peptide as a prognostic marker in critically ill patients. Anesth. Analg., 2006, 102, p. 1809–1815.
2. Müller-Werdan, U. et al. Septische Kardiomyopathie. Intensivmed, 2006, 43, p. 486–497.
3. Uchino, S. et al. Pulmonary artery catheter versus pulse contour analysis: a prospective epidemiological study. Crit. Care, 2006, p. R174.
4. Maeder, M. Sepsis-Associated Myocardial Dysfunction: Diagnostic and Prognostic Impact of Cardiac Troponins and Natriuretic Peptides. Chest, 2006, 129, p. 1349–1366.
5. Charpentier, J. et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit. Care Med., 2004, 32, p. 660–665.
6. Nielsen, L. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. European Journal of Heart Failure, 2004, 6, p. 63–70.
7. Dellinger, R. P. et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intens. Care Med., 2008, 34, p. 17–60.
8. Bouch, D. C., Thompson, J. P. Severity scoring systems in the critically ill. Continuing Education in Anaesthesia, Crit. Care & Pain, 2008, 8, p. 181–185.
9. Minne, L., Abu-Hanna, A., Jonge, E. de Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit. Care, 2009, 12, p. R161.
10. Higgins, T. L. et al. Assessing contemporary intensive care unit outcome: An updated Mortality Probability Admission Model (MPM0-III)*. Crit. Care Med., 2007, 35, p. 827–835.
11. Khwannimit, B., Bhurayanontachai, R. The performance of customised APACHE II and SAPS II in predicting mortality of mixed critically ill patients in a Thai medical intensive care unit. Anaesth. Intensive Care, 2009, 37, p. 784–790.
12. Galrinho, A. et al. Prognostic implications of tissue Doppler in patients with dilated cardiomyopathy. Rev. Port. Cardiol., 2006, 25, p. 781–793.
13. Landesberg, G. et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur. Heart J., 2012, 33, p. 895–903.
14. Sturgess, D. J. et al. Prediction of hospital outcome in septic shock: a prospective comparison of tissue Doppler and cardiac biomarkers. Crit. Care, 2010, 14, p. R44.
15. Sakka, S. et al. Prognostic value of extravascular lung water in critically ill patients. Chest, 2002, 122, p. 2080–2086.
16. Phillips, C., Chesnutt, M., Smith, S. Extravascular lung water in sepsis-associated acute respiratory distress syndrome: indexing with predicted body weight improves correlation with severity of illness and survival. Crit. Care Med., 2008, 36, p. 69–73.
17. Røsjø, H. et al. Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome. Intens. Care Med., 2011, 37, p. 77–85.
18. Liu, D. et al. Prognostic value of plasma N-terminal pro-B-type natriuretic peptide in patients with severe sepsis and septic shock. Sichuan Da Xue Xue Bao Yi Xue Ban, 2011, 42, p. 369–373.
19. Park, B. et al. Prognostic utility of changes in N-terminal pro--brain natriuretic Peptide combined with sequential organ failure assessment scores in patients with acute lung injury/acute respiratory distress syndrome concomitant with septic shock. Shock, 2011, 36, p. 109–114.
20. Cuthbertson, B. H. et al. B-Type natriuretic peptide and the prediction of outcome in patients admitted to intensive care. Anaesthesia, 2005, 60, p. 16–21.
21. Park, M. S. et al. Prognostic utility of changes in N-terminal pro-brain natriuretic Peptide combined with sequential organ failure assessment scores in patients with acute lung injury/acute respiratory distress syndrome concomitant with septic shock. Shock Augusta Ga, 2010, 36, p. 109–114.
22. Banach, M. et al. NT-proBNP levels correlate with organ failure in septic patients: a preliminary report. Postepy higieny i medycyny doswiadczalnej Online, 2006, 60, p. 632–636.
23. Levy, M. M. et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intens. Care Med., 2010, 36, p. 222–231.
24. Vaitsis, J. et al. Use of levosimendan in myocardial dysfunc-tion due to sepsis. Crit. Care, 2009, 13, p. P165.
25. Morelli, A. et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med., 2005, 31, p. 638–644.
26. Tavener, S. A. et al. Immune cell Toll-like receptor 4 is re-quired for cardiac myocyte impairment during endotoxemia. Circ. Res., 2004, 95, p. 700–707.
27. Leon, C. G. et al. Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases. Pharm Res., 2008, 25, p. 1751–1761.
28. Mokart, D. et al. N-terminal pro-brain natriuretic peptide as an early prognostic factor in cancer patients developing septic shock. Critical Care, 2007, 11, p. R37
29. Van Kimmenade, R. R. et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J. Am. Coll. Cardiol., 2009, 53, p. 884–890.
30. Raymond, I. et al. The influence of age, sex and other varia-bles on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart, 2003, 89, p. 745–775.
31. Flierl, M. et al. Molecular events in the cardiomyopathy of sepsis. Molecular Medicine, 2008, 14, p. 327–336.
32. Romero-Bermejo, F. J. et al. Sepsis-induced Cardiomyopathy. Current Cardiology Reviews, 2011, 7, p. 163–183.